Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Afia Ashraf"'
Autor:
Zaki, Maha Mahmoud Mohamed, Afia, Ashraf Ismael Badawy, Ali Al-Nagar, Hasan Ibrahim, Abdel-ra’ouf, Esraa Othman
Publikováno v:
Indian Phytopathology; 20240101, Issue: Preprints p1-8, 8p
Publikováno v:
Pakistan Journal of Phytopathology. 2021, Vol. 33 Issue 1, p55-66. 12p.
Autor:
Ahsan Wahab, Zahoor Ahmed, Abdul Rafae, Afia Ashraf, Aslam Khan, Faiz Anwer, Muhammad Salman Faisal, Kamran Mushtaq, Hamid Ehsan, Tayyab Rehan, Zunairah Shah, Maria Khakwani
Publikováno v:
Expert review of hematology. 13(12)
Multiple myeloma (MM) lacks curative therapy. Therefore, researchers continue to conduct studies in an effort to improve progression-free survival (PFS) and overall survival (OS). Maintenance therapy (MT) after autologous stem cell transplant (ASCT)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c93045d63db113ac04af53d2dcfe8175
https://pubmed.ncbi.nlm.nih.gov/33078986
https://pubmed.ncbi.nlm.nih.gov/33078986
Autor:
Hani M. Babiker, Afia Ashraf, Aqsa Khan, Kamran Mushtaq, Faiz Anwer, Zahoor Ahmed, Tayyab Rehan, Muhammad Shahzeb Khan Khakwani, Aslam Khan, Ahsan Wahab, Maria Khakwani
Publikováno v:
Journal of Clinical Oncology. 38:e20503-e20503
e20503 Background: Multiple Myeloma (MM) is treatable but an incurable hematological malignancy, requiring additional approaches such as maintenance therapy (MT) after autologous-stem cell transplantation. MT aids to achieve deepened response, sustai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fe716db83951426f157d414d4972665b
https://doi.org/10.1200/jco.2020.38.15_suppl.e20503
https://doi.org/10.1200/jco.2020.38.15_suppl.e20503
Autor:
Ammara Majeed, Afia Ashraf, Abdul Rafae, Sanjana Kashinath, Adeela Mushtaq, Fateeha Furqan, Hamza Hassan, Faiz Anwer, Ahmad Iftikhar, Nimra Iftikhar, Faryal Razzaq
Publikováno v:
Journal of Clinical Oncology. 37:e19530-e19530
e19530 Background: Renal impairment (RI) in Multiple Myeloma (MM) adversely affects the prognosis. Removing circulating free light chains via hemodialysis (HD) or plasma exchange (PLEX) along with chemotherapy can improve renal outcomes in MM. Method
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf19cb5281a7fb31d3b8db7c117f6d8d
https://doi.org/10.1200/jco.2019.37.15_suppl.e19530
https://doi.org/10.1200/jco.2019.37.15_suppl.e19530
Autor:
Azka Latif, Midhat Lakhani, Anne Hubben, Atlantis Dawn Russ, Udhayvir Singh Grewal, Fazal Raziq, Rajshekhar Chakraborty, Faiz Anwer, Rujul H Parikh, Vikas Kapoor, Afia Ashraf, Ammara Majeed
Publikováno v:
Journal of Clinical Oncology. 37:e19537-e19537
e19537 Background: To improve outcomes, multiple agents with varied mechanisms of action targeting different multiple myeloma (MM) clones are needed. Methods: Systematic review of ongoing phase I-III clinical trials in newly diagnosed multiple myelom
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f0847401a6c58fbfba3809a931d2217b
https://doi.org/10.1200/jco.2019.37.15_suppl.e19537
https://doi.org/10.1200/jco.2019.37.15_suppl.e19537
Autor:
Ahmad Iftikhar, Afia Ashraf, Faiz Anwer, Nadia Carenina Nunes Cavalcante Parr, Atlantis Dawn Russ, Ahsan Wahab, Abhijeet Kumar, Prem Kumar Thirunagari, Aida Siyahian, Ammara Majeed
Publikováno v:
Journal of Clinical Oncology. 37:e19043-e19043
e19043 Background: Mantle Cell Lymphoma (MCL) is generally treated with rituximab (R) in combination with other drugs. However, treatment for relapsed or refractory (RR) MCL is challenging. For Ibrutinib (Ibr), we aim to determine the efficacy in com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::adba04280edb463499b45e69640d7511
https://doi.org/10.1200/jco.2019.37.15_suppl.e19043
https://doi.org/10.1200/jco.2019.37.15_suppl.e19043
Autor:
Faiz Anwer, Fazal Raziq, Afia Ashraf, Muhammad Salman Faisal, Ahsan Wahab, Prem Kumar Thirunagari, Udhayvir Singh Grewal, Midhat Lakhani, Hamza Hassan, Ammara Majeed
Publikováno v:
Journal of Clinical Oncology. 37:e23182-e23182
e23182 Background: An estimated 20.3 million cancer survivors are expected to be around by 2026. Estimated national expenditure for cancer care in 2017 were $147.3 billion and expected to increase every year. Cancer treatment is complex and requires
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::02d876e2ad7fe25573338b2a352fbe36
https://doi.org/10.1200/jco.2019.37.15_suppl.e23182
https://doi.org/10.1200/jco.2019.37.15_suppl.e23182
Publikováno v:
Pakistan Journal of Nematology; Dec2020, Vol. 38 Issue 2, p130-130, 1p